William J. Newell
Chief Executive Officer
William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of Social Capital Suvretta Holdings Corp IV (NASDAQ: DNAD), Biotechnology Innovation Organization’s (BIO) Health Section, Emerging Company Section and is a member of BIO’s executive committee. He also serves on the board of directors of California Life Sciences (CLS) and is member of CLS’s executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.
Edward Albini, MBA
Chief Financial Officer
Edward Albini has served as our Chief Financial Officer since January 2013. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.
Shabbir Anik, Ph.D.
Chief Technical Operations Officer
Shabbir T. Anik, Ph.D., has served as our Chief Technical Operations Officer since March 2016. From August 2011 to December 2015, Dr. Anik served as Senior Vice President of Technical Operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing medicines for the treatment of cancer. Previously, Dr. Anik served as President and Chief Executive Officer of Althea Technologies Inc., President of Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon Inc. and in various leadership positions at Neurex Corporation and Syntex Inc. Dr. Anik received a B.S. in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison and an M.B.A. from Santa Clara University.
Kristin Bedard, Ph.D.
Senior Vice President, Drug Discovery
Dr. Bedard joined Sutro in February, of 2020, as Vice President of Immunobiology. In March 2021 Dr. Bedard’s role was expanded to Vice President, Discovery, integrating Protein Engineering and Lead Discovery, underpinning all new ADC and cytokine discovery. In August 2022, she was promoted to Senior Vice President, Drug Discovery. Prior to joining Sutro, Dr. Bedard held leadership positions at Kineta, most recently as Chief Scientific Officer, Immuno-oncology and Senior Vice President, Discovery and formerly as Vice President of R&D and Head of Virology. Prior to Kineta, she was a senior fellow at the Fred Hutchinson Cancer Research Center researching cervical and skin cancer. She is the co-inventor of fifteen filed U.S. patent applications for novel classes of antivirals, adjuvants, immune agonists and their corresponding methods of identification. Dr. Bedard volunteers her time to the Healthcare Businesswomen’s Association (HBA) as a founding board member of the Seattle Chapter and a mentor for their professional mentoring program. She received the HBA Everest Award in 2019 for her dedication and leadership. She has also served as a National Institutes of Health reviewer and chairperson for Small Business Innovation Research awards. Dr. Bedard received her B.S. from Pennsylvania State University and earned her Ph.D. from University of California, Irvine.
Annie Chang, MBA
Vice President, Investor Relations
Annie Chang has over 15 years of experience in strategic and advisory roles within the biotechnology, technology, and finance industries. She was previous at Solebury Trout as a Vice President of Investor Relations and led the investor relations and communications programs for small- and mid-cap companies in the biotechnology space. She has worked in the technology industry within corporate development and M&A functions, in asset management at a hedge fund, and in investment banking at Morgan Stanley and J.P. Morgan. Ms. Chang has a B.S. in Finance from New York University and an MBA from INSEAD.
Jane Chung, RPh
Chief Commercial Officer
Jane Chung, RPh has over 20 years of pharmaceutical and biotechnology experience and serves as Chief Commercial Officer since August 2021. From 2015 to 2021, Ms. Chung served in several leadership roles at AstraZeneca, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. Immuno-Oncology, and Senior Commercial Business Director. Prior to that, from 2013 to 2015, Ms. Chung served as Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From 2003 to 2013, she served in various commercial roles for Genentech, Inc., including as Commercial Operations, Manager, Division Manager and Senior Marketing Manager. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc. and on non-profit boards in the science, education, and community development arenas. Ms. Chung received her B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John's University, New York.
Chief People and Communications Officer
Linda Fitzpatrick has served as our Chief People and Communications Officer since August 2018. From January 2008 to August 2018, Ms. Fitzpatrick served as our VP of Human Resources and Communications in the capacity of Senior Advisor. In addition to her strategic consulting practice, she co-founded Parallax Venture Partners, an early stage health care venture fund in April 2002. From October 1992 to March 2002, Ms. Fitzpatrick served as Vice President of Human Resources, Corporate Communications and Operations for Gilead Sciences, Inc. and from February 1985 to September 1992 she served as Director of Investor Relations and Director of Compensation, Benefits and Systems for Genentech, Inc., in addition to heading the human resources and corporate communications strategy for a variety of publicly held biotechnology companies. Ms. Fitzpatrick also serves on a variety of non-profit boards, including board chair roles, in the science, education and community development arenas. Ms. Fitzpatrick received a B.A. in Psychology and Sociology from San Francisco State University.
Trevor Hallam, Ph.D.
President of Research and Chief Scientific Officer
Trevor J. Hallam, Ph.D., has served as our Chief Scientific Officer since December 2010. He was promoted to President, Research and CSO in 2021. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, SmithKline & French Laboratories, Ltd., Glaxo Group Research Ltd., Roche Research and Rhone-Poulenc Rorer. Dr. Hallam received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.
David Pauling, J.D., M.A.
Mr. Pauling joined Sutro in 2011 and has since held positions of increasing responsibility, including Intellectual Property Counsel, Associate General and Senior Intellectual Property Counsel, and most recently Executive Director of Legal Affairs. Prior to joining Sutro, Mr. Pauling practiced law at Jones Day and at Pennie & Edmonds, LLP. Mr. Pauling received his J.D. from Santa Clara University School of Law (magna cum laude), and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.
Brunilda Shtylla, MBA
Senior Vice President, Business Development
Ms. Shtylla worked as an independent consultant since 2012, which included consulting for Genentech since 2013. Prior to this, she held numerous positions at Lifescan, a Johnson & Johnson company, including Associate Director of Partnerships and Product Director, U.S. Brand Marketing. Previously, Ms. Shtylla held roles in Business Development, Technology Transfer, Sales & Operations Planning, Investment Banking and Finance. She received her B.S. from Wayne State University, a M.S. in Mathematics from Youngstown State University and an M.B.A. from Stanford Graduate School of Business.
Venkatesh Srinivasan, Ph.D.
Senior Vice President, Process and Analytical Development
Venkatesh Srinivasan has more than 25+ of experience in Bioprocess Development, Biologics Manufacturing and Tech Transfer in the biopharma industry. From 2011 – 2022, Venkatesh worked at Bayer, where he was most recently, Vice President Global MSAT with responsibilities for the end-to-end support of Bayer’s global internal and external commercial manufacturing network for biopharmaceutical Drug Substances and Drug Products. His team also worked closely with internal and partner pipeline products to ensure manufacturability and as well as evaluation of new technology for the company. Venkatesh started his career at Phyton Biotech, where he successfully developed, scaled-up and commercialized a novel plant cell culture technology platform. At Phyton, Venkatesh held leadership roles in Bioprocess Development, Business Development and in managing Phyton’s intellectual property portfolio. Venkatesh also cofounded GlycoRx, a company focused on developing novel, half-life extended pharmaceutical proteins and peptides based on a unique glycoengineering platform. Venkatesh received his BS in Chemical Engineering from Indian Institute of Technology, Chennai, and his Ph.D. in Chemical Engineering from the State University of New York. He also held post-doctoral appointments at the School of Engineering, Cornell University, and at the Antibody Engineering Laboratory, UC Davis.
Nicki Vasquez, Ph.D.
Chief Portfolio Strategy & Alliance Officer
Dr. Vasquez has more than 25 years of biopharmaceutical discovery research and development experience and has lead our alliance and portfolio management since 2015. Prior to joining Sutro, she was Vice President of Program & Portfolio Management at StemCells, Inc., where she was responsible for establishing project management of research and clinical stage programs exploring HuCNS-SC stem cell therapy for Alzheimer’s Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer’s Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech.
Dr. Nicki Vasquez was recently honored as one of Fierce Pharma 2021 Fiercest Women in Life Sciences. Click the link to read the article, https://www.fiercepharma.com/special-report/women-life-sciences-2021?oly_enc_id=8908A7445778A3R